Loading clinical trials...
Loading clinical trials...
The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Memorial Sloan Kettering Cancer Center
NCT07218913 · Hearing Loss, Metastatic Malignant Germ Cell Tumor, and more
NCT07288580 · Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
NCT06782308 · Tinnitus, Subjective, Tinnitus, Bilateral, and more
NCT04915183 · Hearing Loss, Head and Neck Cancer
NCT05572073 · Sensorineural Hearing Loss, Bilateral
Memorial Sloan Kettering Cancer Center
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions